Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Reduced risk of infections in pts w/ relapsed/refractory myeloma treated w/ BCMA TCE teclistamab by Ig supplementation (all-grade infxns 4.41 vs. 3.15 per pt-yr) and longer dosing intervals (from 6.08 infxns/pt-yr to 2.25).”
Title: Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
Authors: Febe Smits, Kaz Groen, Charlotte Korst, Kris Frerichs, Ilse Kuipers, Sandy Kruyswijk, Maaike de Ruijter, Kazem Nasserinejad, Sonja Zweegman, Niels van de Donk
You can read the Full Article in Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
